Purchase this article with an account.
Qiuhua zhang, Youde Jiang, Robert Ferry, Jena J. Steinle; Novel Beta-Adrenergic Receptor Agonist Prevents Retinal Endothelial Cell Death Through Increased IGFBP3 Levels. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3583.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine whether Compound 49b, a novel β-adrenergic receptor agonist, increases IGFBP3 levels to inhibit apoptosis in the diabetic retina.
Male rats were made diabetic with a single injection of streptozotocin (60mg/kg). Three groups of rats were used: control, diabetic, and diabetic+Compound 49b treated. Compound 49b eye drops (1 mM) were administered daily. After 8 months of treatment, retinal protein levels of IGFBP-3, Bad, Fas, Fas ligand, and Bcl-xl, and cleaved caspase 3 levels were measured by Western blot or ELISA.
Compound 49b eye drops increased IGFBP3 levels (P<0.05 vs. untreated diabetic). Concurrent with the increase in IGFBP3, Compound 49b treatment significantly decreased levels of key pro-apoptotic markers Bad, Fas, Fas ligand, and cleaved caspase 3 (P<0.05 vs untreated diabetic retina).
A novel β-adrenergic receptor agonist, Compound 49b, can significantly increase IGFBP3 levels in the diabetic retina, while decreasing key pro-apoptotic markers. This is the first demonstration of regulation of IGFBP3 by β-adrenergic receptor agonists, as well as a potential anti-apoptotic mechanism for IGFBP3. Future studies will investigate the mechanism by which native IGFBP3 may inhibit retinal endothelial cell death.
This PDF is available to Subscribers Only